Dendreon Corporation (DNDN) Announces Plans To Make PROVENGE® Commercially Available In Europe
3/3/2014 8:17:24 AM
SEATTLE--(BUSINESS WIRE)--Dendreon Corporation today announced that it plans to make PROVENGE® (autologous peripheral blood mononuclear cells activated with PAP-GM-CSF or sipuleucel-T) available in Europe, beginning with Germany and the United Kingdom.
Hey, check out all the research scientist jobs. Post your resume today!
comments powered by